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Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk
of recurrence and who may profit from a more aggressive treatment regimen. Our objective
was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a
marker for recurrent disease, as well as a marker for poor prognosis and lymph node
metastases.
Methods
EDTA-blood samples were obtained from 235 patients with endometrial cancer before pri-
mary surgery. For 36 of these patients, matching blood samples were collected at time of
recurrence. Blood samples were also collected from 78 patients with endometrial hyperpla-
sia. Plasma GDF-15 was measured by an enzyme-linked immunosorbent assay (ELISA).
Preoperative pelvic MRI scans for 141 patients were investigated in parallel for imaging
variables.
Results
Preoperative plasma level of GDF-15 was significantly higher for patients who experienced
recurrence (1780 ng/L; 95% CI; 518–9475 ng/L) than for patients who did not develop recur-
rent disease (1236 ng/L; 95% CI; 307–7030 ng/L) (p<0.001). Plasma levels of GDF-15 at
recurrence (2818 ng/L, 95% CI 2088–3548 ng/L) were significantly higher than plasma lev-
els of GDF-15 measured at time of primary diagnosis (1857 ng/L, 95% CI; 1317–2398 ng/L)
(p = 0.001). High plasma level GDF-15 independently predicts recurrent disease (OR =
3.14; 95% CI 2.10–4.76) and lymph node metastases (OR = 2.64; 95% CI 1.52–4.61).
Patients with high plasma level of GDF-15 had significantly larger tumor volume (p = 0.008).
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Conclusion
Elevated plasma level of GDF-15 is associated with aggressive disease and lymph node
metastasis in endometrial carcinoma. GDF-15 may be helpful in indicating recurrent disease.
Introduction
Endometrial cancer is the most common gynecologic malignancy and the fourth most com-
mon cancer among women in industrialised countries. Incidence is increasing worldwide,
mostly due to the obesity epidemic. The prognosis is good with an overall 5-year survival of
80%, however 15–20% of patients with a presumed low risk disease experience recurrence [1].
Better biomarkers are thus needed in order to identify patients at high risk of recurrence who
may profit from a more aggressive treatment regimen. To date there are no biomarkers for
prognosis routinely available or in widespread use in the clinic and the majority of suggested
markers have been developed for immunohistochemistry based detection in patient tissue
biopsies. However, there has been little focus on identifying markers in preoperative blood
samples [2–4]. Such markers are less invasive than those from biopsy, easily obtainable and
could also be measured repeatedly during the course of the disease. A robust prognostic
plasma biomarker would therefore potentially be highly valuable in the clinic.
Growth differentiation factor-15 (GDF-15), is a distant member of the transforming growth
factor (TGF)-beta superfamily, also named macrophage-inhibitory cytokine -1 (MIC-1), and
was originally identified in activated macrophages [5]. The TGF-beta superfamily has a role in
regulating inflammatory and apoptotic pathways in injured tissues and during disease pro-
cesses. GDF-15 is associated with cell cycle arrest and apoptosis [6]. Expression is dramatically
increased in diseased states, such as acute injury, inflammation and cancer [7]. The prognostic
value of GDF-15 is previously explored in cardiac disease, during pregnancy and in cancer. It
has been suggested as a prognostic biomarker where increased GDF-15 is associated with
increased risk of death at 1 year in patients with non-ST-elevation acute coronary syndrome [8]
as well as in patients with ST-segment elevation and myocardial infarction [9]. In the placenta
GDF-15 is physiologically highly expressed [10] and low expression of GDF-15 is associated
with miscarriages [11]. Elevated levels, however, are associated with diabetes mellitus and pre-
eclampsia [12]. In cancer, GDF-15 overexpression has been reported in malignant melanomas,
prostate-, pancreatic- and colonic cancers [13–16]. Furthermore, elevated serum levels of GDF-
15 are linked to cancer-associated anorexia and weight loss in prostate cancer [17]. In gyneco-
logical malignancies GDF-15 is reportedly an independent marker of aggressive disease in ovar-
ian cancer [18]. For uterine sarcomas, elevated GDF-15 may aid in discriminating aggressive
sarcomas from benign leiomyomas [19], whereas for endometrial cancer increased GDF-15
expression has been reported to predict lymph node metastases and poor survival [20].
In the present study we wanted to explore the applicability of GDF-15 in predicting endo-
metrial carcinoma recurrence. In addition, using an extensive panel of clinicopathological var-
iables including survival, our aim was to validate GDF-15 as a prognostic marker in
endometrial carcinoma and as a possible predictor of lymph node metastases.
Materials and methods
Patient samples
EDTA-blood samples were obtained preoperatively from 235 patients with endometrial cancer
before primary surgery. During time of follow-up 48 patients developed recurrence and blood
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samples were collected from 36 of these patients at time of recurrence. In addition, EDTA-
blood was collected from 78 patients diagnosed with endometrial hyperplasia. All patients
have been diagnosed at Haukeland University Hospital, Norway between 2003 and 2014 and
clinical data as well as blood samples were prospectively collected. Patients signed informed
consent. Regional Committees for Medical and Health Research Ethics approval: 2009/2315
and 2014/1907. The median follow-up in this cohort is 43 months (range 1–189). Blood sam-
ples were centrifuged at 1600 g for 15 min and the plasma was stored at– 80 ˚C until measure-
ment of GDF-15. Distribution of measured GDF-15 plasma level was not influenced by
storage time.
Additionally, data regarding GDF-15 plasma levels were also locally available from an inde-
pendent cohort of 466 endometrial cancer patients previously published [20]. In order to
improve statistical power when predicting lymph node metastases and recurrence, the data
were merged together with the current cohort when performing regression analyses. Data
were missing for recurrence from 47 patients, histological type from 47 patients and myome-
trial infiltration from 49 patients, and the resulting cohort included 603 patients. Regarding
lymph node status, data were missing for 190 patients and preoperative histology missing for
65 patients, and the cohort included 495 patients.
GDF-15 measurements
GDF-15 in plasma was measured by the Human enzyme linked GDF-15 Quantakine ELISA
kit (#DGD150, batch #P153423, R&D Systems, Minneapolis, USA). The ELISA was performed
according to the manufacturer´s instructions. Briefly, 50 μL plasma sample or standard was
added in a 96-well microplate coated with a monoclonal antibody specific for human GDF-15,
and incubated for 2h in room temperature. Following washing, 200 μL human GDF-15 conju-
gate was added and incubated for 1 hour in room temperature. The wells were washed again
before 200 μL of substrate solution were added and incubated for 30 min in room temperature
protected from light, followed by 50 μL of stop solution. The absorbance was measured in a
microplate reader at the wavelength of 450 nm, and plasma concentration of GDF-15 calcu-
lated. To confirm reproducibility, a subset (n = 102) were measured in duplicates. Clinical data
were blinded while performing and evaluating laboratory investigations. The assay has a detec-
tion limit of 20 ng/L, an intraassay imprecision of 10.6% or less, and an interassay imprecision
of 12.2% or less [21].
Preoperative magnetic resonance imaging (MRI)
In parallel, preoperative pelvic MRI scans for 141 patients were assessed to derive the following
imaging variables: endometrial tumor size, signs of deep myometrial invasion, cervical stroma
invasion and lymph node metastases. MRI was conducted on a whole body 1.5-T MRI system
(Siemens Avanto running Syngo v. B17, Erlangen, Germany) using a six channel body coil
applying a standardized imaging protocol [22]. To reduce motion artefacts 20 mg of butylsco-
polamine bromide (Buscopan; Boehringer, Ingelheim, Germany) was administered intrave-
nously. Mean time (range) between MRI examination and surgical staging was 1.5 (0–12)
weeks.
Statistical analyses
Statistical analyses were conducted applying Statistical Program for the Social Sciences (SPSS),
version 24 (IBM Inc. Chicago, IL, USA). All p-values were two sided and p-value of less than
0.05 was considered statistically significant. Pearson Chi-square or Fisher exact test were used
for categorical data. Univariate survival analysis was performed using the Kaplan-Meier
GDF-15 predicts aggressive disease in endometrial cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0210585 January 15, 2019 3 / 13
method and log-rank test, grouping low versus high concentration. Cut-off values for categori-
zation were based on tertiles according to the size of the subgroups and the number of events
in each category. The two lower GDF-15 tertiles were merged due to similar survival. Cut-off
value based on this method was found to be near identical to our previous study [20] (cut-off
in previously published cohort: 1400 ng/L, cut-off in this cohort 1418 ng/L). For analyses
where the cohorts were merged, cut-off value was 1418 ng/L. Low-risk patients were defined
as endometrioid histologic type and grade 1 and 2 disease, and high risk patients as endome-
trioid grade 3 and non-endometrioid. Disease-specific survival was defined as time from pri-
mary treatment to death from endometrial cancer. Patients who died from other causes or
were lost to follow-up were censored at the date of death/last follow-up. Non-parametric tests
Mann Whitney U or Wilcoxon Signed Rank were used for comparison of continuous data
between study groups. Binary logistic regression was used to evaluate the odds ratio (OR) for
lymph node metastases and recurrence.
Results
Plasma GDF-15 associates with poor survival, also in low-risk patients
To validate previous observations that plasma level of GDF-15 is a biomarker for poor progno-
sis in endometrial cancer, plasma level of GDF-15 was determined in an independent patient
population including 235 patients with primary endometrial carcinoma. High level of plasma
GDF-15 was associated with reduced disease-specific survival (p = 0.001, Fig 1A) with 5-year
survival rate of 72.9% compared to 94.1% in patients with low GDF-15. In addition, high
GDF-15 indicated reduced recurrence-free survival (p<0.001, Fig 1B) with 5-year recurrence-
free survival rate of 61.2% compared to 89.3% in endometrial cancer. GDF-15 level was signifi-
cantly higher in patients aged>66 years, and in patients with advanced FIGO stage, non-
endometrioid histologic subtype, high grade and with deep myometrial infiltration (all p-val-
ues�0.003, Table 1). These findings are in line with previous findings from a separate cohort
from our hospital [20]. To further explore the usefulness of plasma GDF-15, we performed
analyses in the low-risk subgroup of patients, defined by endometrioid histology and grade 1
or 2 disease on preoperative curettage specimen (n = 148). Also in this patient subgroup, high
level of plasma GDF-15 was associated with poor prognosis (p = 0.002, Fig 1C) with a 5-year
survival rate of 72.8% compared to 97% in patients with low GDF-15. High age, high grade
Fig 1. Disease-specific survival (A) and recurrence-free survival (B) in 235 patients illustrated by Kaplan Meier curves. Disease-specific survival
in patients with a putative low-risk disease preoperatively, that is endometrioid grade 1 or 2 (C). P-values are calculated by the Mantel-Cox log
rank test. Low GDF-15 is the two lower tertiles, 1. and 2. combined. High GDF-15 is the 3. tertile. Number of cases are given in each category
and in parenthesis number of disease-specific deaths or recurrence.
https://doi.org/10.1371/journal.pone.0210585.g001
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and deep myometrial infiltration were all associated with high levels of GDF-15 (all p-values
�0.007, Table 2) in low-risk patients. BMI did not correlate with increasing plasma concentra-
tions of GDF-15 (R2 0.003).
Plasma GDF-15 does not distinguish between hyperplasias and
endometrial cancer
As the plasma level of GDF-15 has been reported to be elevated in cancers compared to healthy
controls [20], we investigated if plasma GDF-15 also is a marker for progression from hyperplasia
to endometrial cancer. Plasma concentrations of GDF-15 were compared between 78 patients
with endometrial hyperplasias and 235 patients with primary endometrial cancer. There was no
significant difference between plasma levels of GDF-15 in endometrial hyperplasias (1502 ng/L;
95% CI, 1219–1785 ng/L) and primary tumors (1611 ng/L; 95% CI, 1446–1776 ng/L) (p = 0.807).
When performing a more detailed analysis of endometrioid endometrial cancers only, we
observed that the increase of GDF-15 occurs between grade 1 and grade 2 (p = 0.003, Fig 2A).
Elevated plasma level of GDF-15 is associated with recurrent disease
Given the association with aggressive disease, we investigated if GDF-15 could be a marker for
recurrence. When analyzing blood samples from endometrial cancer patients at time of
Table 1. GDF-15 measured in plasma samples from 235 patients with endometrial cancer in relation to clinico-
pathological factors.
Low, n (%) High, n (%) P-value�
Age, y <0.001
<66 86 (84) 16 (16)
�66 71 (53) 62 (47)
FIGO 0.003
I/II 140 (71) 58 (29)
III/IV 17 (46) 20 (54)
Histologic type 0.002
Endometrioid 126 (72) 48 (28)
Non-endometrioid 31 (51) 30 (49)
Non-endometrioid types 0.003
Clear cell 4 (40) 6 (60)
Serous 20 (61) 13 (39)
Carcinosarcomas 3 (25) 9 (75)
Undifferentiated 4 (67) 2 (33)
Histologic grade�� 0.002
Grade 1 76 (84) 15 (16)
Grade 2 27 (55) 22 (45)
Grade 3 18 (64) 10 (36)
Myometrial infiltration 0.001
<50% 101 (75) 33 (25)
�50% 55 (56) 44 (44)
�P-values are calculated by Chi-Square test or Fisher exact test.
��Endometrioid included only.
Low = 1. and 2. tertile
High = 3. tertile
FIGO: International Federation of Gynecology and Obstetrics
https://doi.org/10.1371/journal.pone.0210585.t001
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primary treatment, the preoperative level of plasma GDF-15 was significantly higher for patients
who later experienced recurrence (1780 ng/L; 95% CI; 518–9475 ng/L) than for patients who
did not develop recurrent disease (1236 ng/L; 95% CI; 307–7030 ng/L) (p<0.001, Fig 2B). This
might indicate a potential for GDF-15 in predicting recurrence. To investigate this further,
plasma samples were collected at time of recurrence from 36 patients, and compared to corre-
sponding plasma samples collected at time of primary treatment. For these patients, with avail-
able paired samples, plasma levels of GDF-15 at recurrence (2818 ng/L, 95% CI 2088–3548 ng/
L) were significantly higher than plasma levels of GDF-15 measured at time of primary diagno-
sis (1857 ng/L, 95% CI; 1317–2398 ng/L) (p = 0.001, Fig 2C). This may suggest a role for GDF-
15 in monitoring recurrence.
Plasma GDF-15 independently predicts lymph node metastases and
recurrence
A prediction model for recurrence was calculated from our merged cohort of 603 patients
(described in materials). The cut-off value grouping high and low GDF-15 was 1418 ng/L.
Patients with high plasma level of GDF-15 had significantly higher risk of recurrent disease
(OR = 3.14; 95% CI 2.10–4.76) in univariate analysis. In the multivariate model, after adjusting
for age, postoperative histology and depth of myometrial infiltration, the predictive value
Table 2. GDF-15 in plasma samples in relation to clinicopathological factor in patients with preoperative low-risk
staging�.
Low, n (%) High, n (%) P-value#
Age, years 0.005
<66 59 (83) 12 (17)
�66 48 (62) 19 (38)
FIGO 0.36
I/II 98 (74) 35 (26)
III/IV 9 (60) 6 (40)
Histologic type 0.218
Endometrioid 103 (74) 37 (26)
Non-endometrioid 4 (50) 4 (50)
Non-endometrioid types 0.242
Clear cell 0 1 (100)
Serous 3 (50) 3 (50)
Carcinosarcomas 1 (100) 0
Histologic grade�� 0.007
Grade 1 70 (82) 15 (18)
Grade 2 24 (57) 18 (43)
Grade 3 5 (56) 4 (44)
Myometrial infiltration 0.007
<50% 73 (80) 18 (20)
�50% 34 (60) 23 (40)
�Low-risk patients defined as endometrioid histology and grade 1 or grade 2 disease on preoperative curettage.
��Endometrioid included only.
#P-values are calculated by Chi-square test or Fisher exact test.
Low = 1. and 2. tertile
High = 3. tertile
FIGO: International Federation of Gynecology and Obstetrics
https://doi.org/10.1371/journal.pone.0210585.t002
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remained significant with an adjusted OR of 1.99 (95% CI 1.23–3.22, Table 3). Furthermore, in
the merged cohort of 495 patients with lymph node status (also described in materials and cut-
off value of 1418 ng/L), high plasma level of GDF-15 was significantly associated with lymph
node metastases (OR = 2.64; 95% CI 1.52–4.61) in univariate analysis. In multivariate analysis,
adjusting for preoperative histological risk (high; endometrioid grade 3 or non-endometrioid
versus low; endometrioid grade 1 or 2) the predictive value of GDF-15 remained significant
with an adjusted OR of 2.49 (95% CI 1.42–4.37, Table 4). Age was not significant in in
Fig 2. Box plots showing plasma level of GDF-15 in hyperplasias and grade 1–3 (A), in patients who experienced
recurrence during their follow-up and in patients who did not (B) and plasma level of GDF-15 in paired samples at
time of primary diagnosis and at time of recurrence (C). Number of cases are given. P-values are calculated by the
Mann Whitney U test in independent samples and Wilcoxon Signed Rank test in related samples. �Endometrioid
included only.
https://doi.org/10.1371/journal.pone.0210585.g002
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univariate analysis and was therefore not included in the multivariate analysis. Statistical
power was too low to perform the analysis in the independent cohort of 235 patients.
High tumor volume detected by MRI is associated with high plasma GDF-
15
In order to further validate GDF-15 as a preoperative marker of prognosis, we compared
plasma levels of GDF-15 with imaging variables from routine preoperative MRI (n = 141).
Patients with high plasma level of GDF-15 had significantly larger tumor volume; with mean
tumor size of 17 ml (95% CI: 12–22 ml) in patients with low GDF-15 as opposed to mean
tumor size of 27 ml (95% CI: 13–40 ml) in patients with high GDF-15 (p = 0.008). Also, high
plasma level of GDF-15 was associated with MRI assessed deep myometrial infiltration
(p = 0.05) and cervical stroma invasion (p = 0.03, Table 5).
Discussion
Biomarkers derived from blood samples are easily available and has been less explored com-
pared to tissue biomarkers in endometrial cancer. GDF-15 in plasma has previously been pro-
posed as a biomarker in endometrial cancer [20], and has also been suggested as a serum
biomarker in patients with prostate, pancreatic and colon cancers [13, 14, 16]. In addition,
Table 3. Prediction of recurrence in 603 patients with endometrial cancer, univariate and multivariate logistic regression.
Variable N Univariate OR 95% CI P Multivariate OR 95% CI P
Age <0.001 0.043
603 1.05 1.03–1.07 1.02 1.00–1.05
Histology <0.001 <0.001
Endometrioid 492
Non-endometrioid 111 4.50 2.86–7.09 3.72 2.29–6.05
Myometrial infiltration <0.001
<50% 390 <0.001
�50% 213 2.67 1.77–4.04 2.27 1.45–3.55
GDF-15 <0.001 0.005
Low 419
High tertile 184 3.14 2.07–4.76 1.99 1.23–3.22
Variables significant in univariate analyses were used in the final multivariate model.
https://doi.org/10.1371/journal.pone.0210585.t003
Table 4. Prediction of lymph node metastases in 495 patients with endometrial cancer, univariate and multivariate logistic regression.
Variable N Univariate OR 95% CI P Multivariate OR 95% CI P
Curretage histology 0.014 0.036
Low risk� 373
High risk�� 122 2.06 1.16–3.66 1.87 1.04–3.37
GDF-15 0.001 0.001
Low 346
High tertile 149 2.64 1.52–4.61 2.49 1.42–4.37
Variables significant in univariate analyses were used in the final multivariate model.
�Low-risk patients defined as endometrioid histology and grade 1 or grade 2 disease on preoperative curettage.
��High-risk patients defined as endometrioid histology and grade 3 disease or non-endometrioid histology on preoperative curettage.
https://doi.org/10.1371/journal.pone.0210585.t004
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GDF-15 has been proposed as a general predictor of cardiovascular disease [23] also in appar-
ently healthy women [24]. In this study, we validate that high level of plasma GDF-15 is associ-
ated with clinical characteristics depicting aggressive disease and poor survival in endometrial
cancer. In previous studies by Staff et al. elevated plasma level of GDF-15 was associated with
aggressive histologic types, lymph node metastases, reduced recurrence-free survival, and
death due to endometrial cancer [20]. Our results are in line with these findings and validate
GDF-15 as a prognostic marker in endometrial carcinoma.
Plasma biomarkers might be useful for screening if a marker could detect early stages of dis-
ease. However, we did not find that plasma levels of GDF-15 distinguish between hyperplasias
and grade 1 endometrioid endometrial cancers. Previous reports have identified an increase in
plasma GDF-15 from healthy controls to cancer [14, 16, 20]. It is interesting that hyperplasias
show similarly high plasma GDF-15 compared to grade 1 endometrioid endometrial cancers.
This may indicate that elevation of GDF-15 is an early event and occurs simultaneously with
development of hyperplasias. It has previously been reported that serum GDF-15 levels pro-
gressively increase from premalignant colonic lesions to cancer initiation with a further
increase of plasma levels GDF-15 at time of metastasis [16]. It is known that GDF-15 can
induce various pleiotropic effects during cancer progression by negatively or positively modu-
lating cell proliferation, differentiation, apoptosis, invasion, and metastases, dependent of can-
cer cell types, disease stage, and tumor microenvironment [25]. However, the function of
GDF-15 is not yet fully understood. A more thorough investigation of GDF-15 in early stages
of disease should include large cohorts of controls and hyperplasias, preferentially also with
repeated sampling of individual patients.
For endometrial cancer, there is a need to preoperatively identify patients with aggressive
disease to stratify for optimal treatment. Presently, preoperative diagnosis relies on risk classifi-
cation based on a preoperative biopsy and at some centers, preoperative imaging, preferen-
tially MRI, is included. Addition of an easily obtainable serum biomarker could add relevant
information. Importantly, we find that in patients with putative low risk based on preoperative
histology (endometrioid grade 1 or 2), high level of GDF-15 predicts poor prognosis and is
associated with aggressive features in endometrial cancer. In contrast, low-risk patients with
low levels of GDF-15 have a 5-year survival of 97%. This suggests a promising role for GDF-15
in confirming preoperatively that some putative low-risk patients have an excellent prognosis,
supporting the clinical value of plasma GDF-15 in endometrial cancer treatment.
Additionally important for treatment of endometrial cancer patients is the ability to identify
patients with risk of recurrence. We here find that in preoperative samples, plasma levels of
GDF-15 are higher for patients that later experience recurrent disease compared to patients
Table 5. Clinical characteristics on preoperative MRI in 141 patients in relation to plasma level of GDF-15.
Low n (%) High n (%) P- value�
Myometrial infiltration 0.05
<50% 63 (85) 11 (15)
�50% 48 (72) 19 (28)
Cervical stroma affection 0.03
no 90 (84) 17 (16)
yes 7 (58) 5 (42)
�P-values are calculated by Chi-Square test.
Low = 1. and 2. tertile
High = 3. tertile
https://doi.org/10.1371/journal.pone.0210585.t005
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that do not experience recurrence. Further analyses showed the same for paired samples,
where level of GDF-15 increased in samples from primary treatment to samples obtained at
time of recurrence. When adjusting for age, histology and myometrial infiltration, high plasma
level of GDF-15 was an independent marker for predicting recurrence. To the best of our
knowledge we demonstrate for the first time that elevated levels of GDF-15 may be helpful in
follow-up of patients to detect recurrence. Although the sample size of 36 paired samples is
low, the results are promising and indicating a role for GDF-15 in monitoring recurrence. The
increase of GDF-15 in aggressive disease and recurrence has been reported in gene- expression
signatures from circulating tumor cells [26], further emphasizing our findings. Measuring
GDF-15 in plasma from patients with endometrial cancer may be helpful when selecting
women who are likely to profit from adjuvant therapy after primary treatment. Monitoring
plasma levels of GDF-15 during follow-up can potentially also guide the recommended fre-
quency of follow-up examinations including diagnostic imaging such as MRI or Computer
Tomography (CT) after primary treatment.
Interestingly, GDF-15 was superior to histological risk classification in predicting meta-
static lymph nodes. GDF-15 could therefore be helpful as an indicator of lymph node metasta-
ses and when selecting women for lymphadenectomy. The value of lymph node sampling is
controversial and studies are not convincing when evaluating survival benefit and short- and
long term complications for the patients who undergo lymphadenectomy [27]. Thus, markers
for better prediction of lymph node metastasis may be valuable in the clinic. Novel techniques,
such as sentinel lymph node mapping in endometrial carcinoma is increasingly acknowledged
[28], however it has limitations among others in relation to obese patients and is still not
implemented in most countries, thus a marker in blood samples is still clinically relevant.
Using imaging methods as an adjunct to preoperative serum or tumor biopsy risk stratifica-
tion may be a useful clinical tool. We demonstrated correlation between plasma GDF-15 and
MRI determined tumor size and cervical infiltration. MRI has been reported to outperform
that of endocervical curettage for preoperative prediction of cervical stromal invasion [29].
Also, for differentiation of low grade endometrial cancer from endometrial hyperplasia, preop-
erative MRI and FDG-PET yield promising imaging markers [30]. Imaging markers may thus
be better than plasma GDF-15 in detecting early disease since the elevation of GDF-15 seems
to occur prior to cancer development. However, the patient population with available imaging
data should be larger to validate these findings.
Endometrial cancer is associated with both obesity and high age, factors known to increase
the risk of comorbidity such as cardiovascular disease. Cardiovascular disease is not systemati-
cally reported in our cohort, and could potentially have biased our results due to its association
with high plasma GDF-15 [23, 24]. However, the use of disease-specific survival in our survival
analyses and the identified association with both high grade and myometrial infiltration,
which is independent of comorbidity and high age, support that GDF-15 specifically detects
aggressive endometrial cancer in our cohort. Also, given the association that high plasma level
of GDF-15 decreases time to recurrence, further emphasizes that GDF-15 is increased due to
the patient’s cancer status as reduced time to recurrence is not likely to be influenced by car-
diovascular disease.
Few biomarkers have so far been identified from plasma [2–4] and blood derived markers
would be useful in clinical practice as they are less invasive for the patient, are relatively inex-
pensive and may prove helpful both for preoperative prognostication and in detecting recur-
rent disease during follow-up. Monitoring plasma levels of GDF-15 during follow-up can
potentially guide clinicians when to refer patients to renewed diagnostic imaging by MRI and
Computer Tomography (CT) or FDG PET-CT to detect recurrence. Robust plasma markers
GDF-15 predicts aggressive disease in endometrial cancer
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could thus represent a valuable tool in clinical practice. However, further and larger studies are
needed to further evaluate GDF-15 as a plasma marker for recurrence.
We conclude that elevated levels of plasma GDF-15 is associated with an aggressive clinical
phenotype and lymph node metastasis in endometrial carcinomas. Elevated GDF-15 is also a
marker of recurrent disease at time of recurrence. The clinical value of plasma GDF-15 for pre-
diction of lymph node metastases, prognostication and as a marker of recurrent disease, how-
ever, needs to be validated in larger patient cohorts and in clinical trials prior to potential
implementation in the clinic.
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